Meeting
2023 ASCO Quality Care Symposium
Quality of life comparison based on testosterone recovery after androgen deprivation therapy in patients cured from high-risk prostate cancer: Long term data from a phase III trial.
Authors
Abdenour Nabid
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
Abdenour Nabid, Nathalie Carrier, André-Guy Martin, Jean-Paul Bahary, Peter Vavassis, Sylvie Vass, Boris Bahoric, Robert Archambault, Francois Vincent, Redouane Bettahar, Luis Souhami
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship
Sub Track
Integrating Patient Experience Assessment and Patient Reported Outcomes Into Practice
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 333)
DOI
10.1200/OP.2023.19.11_suppl.333
Abstract #
333
Poster Bd #
E18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial.
First Author: Rana R. McKay
Poster
2023 ASCO Genitourinary Cancers Symposium
Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): Individual patient data meta-analysis from the MARCAP Consortium.
First Author: Wee Loon Ong
Poster
2017 ASCO Annual Meeting
A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP).
First Author: Stephen Andrew Mihalcik
Poster
2017 Genitourinary Cancers Symposium
Is there a relationship between testosterone levels at the end of short-term androgen deprivation therapy and outcomes in intermediate risk prostate cancer? Prospective data from a phase III trial.
First Author: Abdenour Nabid